Stifel has initiated with a Buy rating and a price target of $11. Analyst Paul Matteis expects the company to be well positioned over the next ~18 months to derisk COMP360 (psilocybin) in two ...

Magic mushrooms, fungi with psilocybin, have long been prized across various cultures for their hallucinogenic properties. More recently, their potential to treat intractable conditions like ...

Psilocybin, a compound in magic mushrooms, shows potential in treating mild repetitive head injuries. In a study with adult female rats, psilocybin treatment restored normal brain function after ...